Sensile Medical enters into deal with scPharmaceuticals
To develop advanced subcutaneous drug delivery system
Sensile Medical, a Swiss manufacturer of medical devices, has entered into a partnership and supply agreement with scPharmaceuticals to develop and manufacture an automated patch minipump to deliver heart failure therapy furosemide under the skin using a very small needle.
Terms of the agreement were not disclosed.
Furosemide is a diuretic that forms the cornerstone of heart failure therapy and is currently used in tablet form or in solution for intravenous administration. Boston, MA, US-based scPharmaceuticals has developed a subcutaneous formulation of the drug and will use Sensile Medical’s patented SenseCore technology to deliver the drug in a patient-friendly and automated way.
scPharmaceuticals will start its late-stage clinical development phase in the near future and expects to submit a New Drug Application for the furosemide drug device combination no later than Q1 of 2015.
‘We are very pleased to enter this collaboration with scPharmaceuticals,’ said Derek Brandt, CEO of Sensile Medical. ‘We believe that our micro pump technology has the potential to address some important therapeutic and economic challenges that the medical community is facing today.’
Pieter Muntendam, President and CEO of scPharmaceuticals, added: ‘The Affordable Care Act has created an urgent need for novel therapies that offer benefits comparable to those achieved by intravenously administered drugs in the hospital, but which can be administered anytime, anywhere by the patient.
‘The SenseCore Micro-Pump technology stands out because of its precision and the unique and cost-effective two component design.’